paroxetine has been researched along with mirtazapine in 77 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.30) | 18.7374 |
| 1990's | 3 (3.90) | 18.2507 |
| 2000's | 39 (50.65) | 29.6817 |
| 2010's | 29 (37.66) | 24.3611 |
| 2020's | 5 (6.49) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Cortizo, L; García, N; Innerárity, A; Labeaga, L; Mosquera, R; Orjales, A; Pumar, MC; Toledo, A | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Buck, LB; Petrascheck, M; Ye, X | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Cleves, AE; Jain, AN; Kirshner, D; Langham, JJ; Spitzer, R | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Claxton, CR; Curran, RE; Harradine, PJ; Hutchison, L; Littlewood, P; Martin, IJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Smith, DF | 1 |
| Farah, A | 1 |
| Thompson, C | 1 |
| Nutt, DJ | 1 |
| Besson, A; Blier, P; de Montigny, C; Haddjeri, N | 1 |
| Benkert, O; Kohnen, R; Szegedi, A | 1 |
| Kremer, C; Quitkin, FM; Taylor, BP | 1 |
| Benkert, O; Muller, M; Szegedi, A | 1 |
| Lima, L; Urbina, M | 1 |
| Baghai, TC; Bondy, B; Minov, C; Möller, HJ; Rupprecht, R; Schüle, C; Schwarz, MJ; Zwanzger, P | 1 |
| Angus, M; Crawford, GM; Hamilton, L; Wade, A; Wilson, R | 1 |
| Anghelescu, I; Benkert, O; Klawe, C; Kohnen, R; Müller, MJ; Szegedi, A | 1 |
| Hindmarch, I; Johnsen, S; Meadows, R; Ridout, F | 1 |
| Kremer, C; Murphy, GM; Rodrigues, H; Schatzberg, AF | 1 |
| Kremer, C; Murphy, GM; Rodrigues, HE; Schatzberg, AF | 1 |
| Olivier, B; Waldinger, MD; Zwinderman, AH | 1 |
| Grauer, MT; Holsboer, F; Uhr, M | 1 |
| Bateman, DN; Chick, J; Good, AM; Kelly, CA; Masterton, G | 1 |
| Lynch, A; Madjlessi, A | 1 |
| Knapp, M; Patel, A; Romeo, R; Thomas, C | 1 |
| Hartter, S | 1 |
| Hollander, SB; Kremer, C; Murphy, GM; Rodrigues, HE; Schatzberg, AF | 1 |
| Dahmen, N; Kohnen, R; Müller, MJ; Rujescu, D; Stassen, HH; Szegedi, A; Tadic, A | 3 |
| Baccichet, E; Carreira, I; Lima, L; Peña, S; Urbina, M | 1 |
| Albertazzi, P | 1 |
| Bajbouj, M; Danker-Hopfe, H; Gallinat, J; Hellen, F; Lang, UE; Lisanby, SH; Neu, P; Vesper, J | 1 |
| Connor, K; Davidson, JR; Vaishnavi, S | 1 |
| Conrad, R; Geiser, F; Imbierowicz, K; Liedtke, R; Wegener, I | 1 |
| Ahned, N; Pearce, S; Varas, GM | 1 |
| Blier, P; Boucher, N; de Montigny, C; Debonnel, G; Gobbi, G; Hébert, C; Turcotte, JE | 1 |
| Lazzeroni, LC; Murphy, GM; Ryan, HS; Sarginson, JE; Schatzberg, AF | 1 |
| Nierenberg, AA; Schutte, AJ; Simmons, JH; Thase, ME; van Oers, HJ; Vrijland, P | 1 |
| Cao, L; Chen, J; Cui, X; Fang, Y; Gao, K; Hong, W; Jiang, K; Nierenberg, AA; Wang, Y; Wu, Z; Xu, Y; Yi, Z; Yuan, C | 1 |
| Deshpande, A; Ing, A; Rizo, C; Seeman, N | 1 |
| Cho, HB; Jeong, HS; Jung, JY; Kim, J; Kim, JE; Kim, TS; Lyoo, IK; Shin, E; Yoon, SJ | 1 |
| Fitzgerald, P; Hannon, B; Murphy, M | 1 |
| Lee, KU; Lee, YM | 1 |
| Schruers, KR; Schutters, SI; van Megen, HJ; Van Veen, JF; Westenberg, HG | 1 |
| Blum, WF; Colla, M; Daseking, E; Deuschle, M; Gilles, M; Heuser, I; Kopf, D; Krumm, B; Lederbogen, F; Schilling, C; Weber-Hamann, B; Wudy, SA | 1 |
| Fazel, M; Goldring, L; Reed, RV | 1 |
| Arterburn, D; Bogart, A; Boudreau, DM; Haneuse, S; Simon, G; Theis, MK; Westbrook, E | 1 |
| Atigari, OV; Healy, D; Jabeen, Q; Kelly, AM | 1 |
| Helmreich, I; Hiemke, C; Kohnen, R; König, J; Szegedi, A; Tadić, A; Wagner, S | 1 |
| Chiu, HF; Correll, CU; Feng, L; Feng, Y; Geng, Y; Guo, T; Hu, CQ; Lai, KY; Ungvari, GS; Wang, G; Xiang, YT; Xiao, L | 1 |
| Datka, W; Dudek, D; Gurwitz, D; Kmiotek, K; Obuchowicz, M; Oved, K; Pilc, A; Rzezniczek, S; Shomron, N; Siwek, M | 1 |
| Cipriani, A; Coghill, D; Cohen, D; Cuijpers, P; Del Giovane, C; Hazell, P; Hetrick, SE; Leucht, S; Liu, L; Liu, Y; Michael, KD; Pu, J; Qin, B; Ravindran, AV; Whittington, C; Xie, P; Yang, L; Zhang, Y; Zhou, X | 1 |
| Jia, L; Jiang, SM; Liu, J; Shi, MM; Xu, MZ | 1 |
| Li, Y; Lu, X; Tao, C; Yan, W | 1 |
| Reich, A; Szepietowski, JC | 1 |
| Mai, SM; Xiang, YT; Yang, XH; Zhang, YF; Zheng, W; Zhong, HQ | 1 |
| Bahar, MA; Bos, JHJ; Hak, E; Wang, Y; Wilffert, B | 1 |
| Carleton, BC; Etminan, M; Guo, MY; Kezouh, A; Kim, DD; Procyshyn, RM; Samii, A | 1 |
| Uguz, F | 1 |
| Cipriani, A; Furukawa, TA; Ikeda, K; Imai, H; Maruo, K; Noma, H; Shinohara, K; Tanaka, S; Yamawaki, S | 1 |
| Bai, Y; Chen, R; Chen, X; Feng, Y; Gao, C; Gao, Y; Gillespie, A; Ma, X; Pan, X; Wang, G; Wang, X; Xiao, L; Xie, Y; Xu, X; Zhou, J; Zhu, X | 1 |
| Červeňová, J | 1 |
| Badcock, PB; Bailey, AP; Cox, GR; Hetrick, SE; McKenzie, JE; Meader, N; Merry, SN; Moller, CI; Sharma, V | 1 |
| Ipser, JC; Phillips, NJ; Stein, DJ; Williams, T | 1 |
| Hasegawa, C; Komahashi-Sasaki, H; Maehara, R; Shimoda, K; Yasui-Furukori, N | 1 |
| Hatano, M; Ikuta, T; Iwata, N; Kishi, T; Matsuda, Y; Okuya, M; Sakuma, K | 1 |
14 review(s) available for paroxetine and mirtazapine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Mirtazapine versus selective serotonin reuptake inhibitors.
Topics: Antidepressive Agents, Tricyclic; Citalopram; Clinical Trials as Topic; Depressive Disorder; Fluoxetine; Humans; Mianserin; Mirtazapine; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 1999 |
Care of depressed patients with anxiety symptoms.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Citalopram; Clinical Trials as Topic; Comorbidity; Depressive Disorder; Fluoxetine; Humans; Mianserin; Mirtazapine; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 1999 |
An overview of the clinical efficacy of mirtazapine.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder; Humans; Mianserin; Mirtazapine; Paroxetine; Selective Serotonin Reuptake Inhibitors; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2002 |
Noradrenergic and serotonergic modulation to treat vasomotor symptoms.
Topics: Citalopram; Cyclohexanols; Female; Fluoxetine; Hot Flashes; Humans; Menopause; Mianserin; Mirtazapine; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Trazodone; Venlafaxine Hydrochloride | 2006 |
Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Citalopram; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Fluvoxamine; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Patient Dropouts; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Remission Induction; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; Young Adult | 2010 |
[Posttraumatic stress disorder].
Topics: Adolescent; Adult; Antidepressive Agents; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Cross-Cultural Comparison; Cross-Sectional Studies; Diagnosis, Differential; Eye Movement Desensitization Reprocessing; Female; Guideline Adherence; Humans; Life Change Events; Male; Mianserin; Mirtazapine; Paroxetine; Stress Disorders, Post-Traumatic | 2013 |
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Confounding Factors, Epidemiologic; Depressive Disorder, Major; Desipramine; Double-Blind Method; Drug Administration Schedule; Duloxetine Hydrochloride; Evidence-Based Medicine; Fluoxetine; Humans; Imipramine; Mianserin; Mirtazapine; Nortriptyline; Paroxetine; Piperazines; Randomized Controlled Trials as Topic; Research Design; Sertraline; Treatment Outcome; Triazoles; Venlafaxine Hydrochloride | 2016 |
Itch in Psoriasis Management.
Topics: Adaptation, Psychological; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Doxepin; Histamine Antagonists; Humans; Mianserin; Mirtazapine; Paroxetine; Pruritus; Psoriasis; Social Support; Thalidomide; Ultraviolet Therapy | 2016 |
Wuling Capsule for Major Depressive Disorder: A Meta-analysis of Randomised Controlled Trials.
Topics: Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; China; Depressive Disorder, Major; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Sertraline; Treatment Outcome; Young Adult | 2016 |
Exploratory analyses of effect modifiers in the antidepressant treatment of major depression: Individual-participant data meta-analysis of 2803 participants in seven placebo-controlled randomized trials.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; Depression; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Japan; Male; Middle Aged; Mirtazapine; Paroxetine; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Treatment Outcome; Venlafaxine Hydrochloride | 2019 |
New generation antidepressants for depression in children and adolescents: a network meta-analysis.
Topics: Adolescent; Antidepressive Agents; Bias; Child; Citalopram; Depressive Disorder, Major; Desvenlafaxine Succinate; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Mirtazapine; Network Meta-Analysis; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Suicidal Ideation; Venlafaxine Hydrochloride; Vilazodone Hydrochloride; Vortioxetine | 2021 |
Pharmacotherapy for post traumatic stress disorder (PTSD).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amitriptyline; Antidepressive Agents; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Humans; Middle Aged; Mirtazapine; Paroxetine; Selective Serotonin Reuptake Inhibitors; Stress Disorders, Post-Traumatic; Young Adult | 2022 |
Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
Topics: Adult; Amitriptyline; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Desvenlafaxine Succinate; Duloxetine Hydrochloride; Female; Fluoxetine; Fluvoxamine; Humans; Mirtazapine; Network Meta-Analysis; Paroxetine; Randomized Controlled Trials as Topic; Reboxetine; Sertraline; Venlafaxine Hydrochloride; Vortioxetine | 2023 |
24 trial(s) available for paroxetine and mirtazapine
| Article | Year |
|---|---|
Relief of SSRI-induced sexual dysfunction with mirtazapine treatment.
Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety Disorders; Drug Therapy, Combination; Female; Fluoxetine; Humans; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Sexual Dysfunctions, Psychological; Treatment Outcome | 1999 |
Mirtazapine compared with paroxetine in major depression.
Topics: Adult; Aged; Ambulatory Care; Antidepressive Agents, Tricyclic; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Psychiatric Status Rating Scales; Severity of Illness Index; Treatment Outcome | 2000 |
Substance P serum levels are increased in major depression: preliminary results.
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Enzyme-Linked Immunosorbent Assay; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Substance P; Time Factors | 2003 |
A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Depressive Disorder; Double-Blind Method; Fatigue; Female; Headache; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Nausea; Paroxetine; Primary Health Care; Severity of Illness Index; Sweating; Treatment Outcome | 2003 |
Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents, Tricyclic; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Prognosis; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Survival Analysis; Treatment Outcome | 2003 |
A placebo controlled investigation into the effects of paroxetine and mirtazapine on measures related to car driving performance.
Topics: Adrenergic alpha-Antagonists; Adult; Antidepressive Agents; Automobile Driving; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Mianserin; Mirtazapine; Paroxetine; Reaction Time; Selective Serotonin Reuptake Inhibitors; Sleep; Sleep Stages; Surveys and Questionnaires | 2003 |
The apolipoprotein E epsilon4 allele and antidepressant efficacy in cognitively intact elderly depressed patients.
Topics: Aged; Aged, 80 and over; Alleles; Antidepressive Agents; Apolipoproteins E; Chromatography, High Pressure Liquid; Cognition; Depression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Genotype; Geriatric Psychiatry; Humans; Male; Mianserin; Mirtazapine; Neuropsychological Tests; Paroxetine; Psychiatric Status Rating Scales; Time Factors; Treatment Outcome | 2003 |
Pharmacogenetics of antidepressant medication intolerance.
Topics: Aged; Alleles; Antidepressive Agents; Cytochrome P-450 CYP2D6; Cytosine; Double-Blind Method; Drug Tolerance; Female; Genetic Markers; Genotype; High-Temperature Requirement A Serine Peptidase 2; Humans; Male; Mianserin; Mirtazapine; Mitochondrial Proteins; Paroxetine; Polymorphism, Single Nucleotide; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Serine Endopeptidases; Thymine | 2003 |
Antidepressants and ejaculation: a double-blind, randomized, fixed-dose study with mirtazapine and paroxetine.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antidepressive Agents; Chi-Square Distribution; Confidence Intervals; Double-Blind Method; Ejaculation; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Sexual Dysfunction, Physiological | 2003 |
The cost-effectiveness of mirtazapine versus paroxetine in treating people with depression in primary care.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Cost-Benefit Analysis; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Primary Health Care; Prospective Studies; Psychiatric Status Rating Scales; Quality of Life; Treatment Outcome | 2004 |
Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression.
Topics: Adrenergic alpha-Antagonists; Aged; Ambulatory Care; Depressive Disorder, Major; Female; Genetic Markers; Genotype; Humans; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mianserin; Mirtazapine; Nerve Tissue Proteins; Paroxetine; Pharmacogenetics; Polymorphism, Genetic; Proportional Hazards Models; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Treatment Outcome | 2004 |
The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Female; Gene Frequency; Genetic Linkage; Genotype; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Monoamine Oxidase; Paroxetine; Polymorphism, Single Nucleotide; Sex Characteristics; Time Factors; Treatment Outcome | 2007 |
Motor cortex excitability after vagus nerve stimulation in major depression.
Topics: Adult; Benzodiazepines; Citalopram; Clomipramine; Clozapine; Depressive Disorder; Doxepin; Drug Therapy, Combination; Electric Stimulation; Female; Humans; Lamotrigine; Lithium Carbonate; Male; Mianserin; Middle Aged; Mirtazapine; Morpholines; Motor Cortex; Neural Conduction; Neural Inhibition; Olanzapine; Paroxetine; Psychiatric Status Rating Scales; Reboxetine; Tranylcypromine; Triazines; Vagus Nerve; Valproic Acid | 2007 |
A monoamine oxidase B gene variant and short-term antidepressant treatment response.
Topics: Adult; Alleles; Antidepressive Agents; Data Interpretation, Statistical; Depressive Disorder, Major; DNA; Double-Blind Method; Female; Humans; Introns; Male; Mianserin; Middle Aged; Mirtazapine; Monoamine Oxidase; Paroxetine; Psychiatric Status Rating Scales; Reverse Transcriptase Polymerase Chain Reaction; Selective Serotonin Reuptake Inhibitors | 2007 |
Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Chromatography, High Pressure Liquid; Compliance; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electrochemistry; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Psychiatric Status Rating Scales; Severity of Illness Index; Time Factors; Treatment Outcome | 2009 |
FKBP5 polymorphisms and antidepressant response in geriatric depression.
Topics: Aged; Antidepressive Agents; Depression; Double-Blind Method; Female; Genetic Variation; Geriatrics; Humans; Male; Mianserin; Mirtazapine; Paroxetine; Polymorphism, Genetic; Sequence Analysis, DNA; Tacrolimus Binding Proteins; Treatment Outcome | 2010 |
Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; China; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Drug Resistance; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Pilot Projects; Psychiatric Status Rating Scales; Remission Induction; Treatment Outcome; Venlafaxine Hydrochloride | 2010 |
Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Anxiety Disorders; Depressive Disorder, Major; Dose-Response Relationship, Drug; Humans; Male; Mianserin; Mirtazapine; Paroxetine; Prospective Studies; Treatment Outcome; Young Adult | 2011 |
Paroxetine augmentation in patients with generalised social anxiety disorder, non-responsive to mirtazapine or placebo.
Topics: Adrenergic alpha-Antagonists; Adult; Anxiety Disorders; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunctions, Psychological; Treatment Outcome | 2011 |
Leptin plasma concentrations increase during antidepressant treatment with amitriptyline and mirtazapine, but not paroxetine and venlafaxine: leptin resistance mediated by antihistaminergic activity?
Topics: Adult; Aged; Aged, 80 and over; Amitriptyline; Analysis of Variance; Antidepressive Agents; Biomarkers; Body Mass Index; Cyclohexanols; Depression; Female; Humans; Leptin; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Time Factors; Treatment Outcome; Up-Regulation; Venlafaxine Hydrochloride; Weight Gain; Young Adult | 2013 |
Hamilton depression rating subscales to predict antidepressant treatment outcome in the early course of treatment.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Predictive Value of Tests; Psychiatric Status Rating Scales; Remission Induction; ROC Curve; Time Factors; Treatment Outcome | 2015 |
Measurement-Based Care Versus Standard Care for Major Depression: A Randomized Controlled Trial With Blind Raters.
Topics: Adult; Antidepressive Agents; Clinical Decision-Making; Depressive Disorder, Major; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Pilot Projects; Psychiatric Status Rating Scales; Severity of Illness Index; Treatment Outcome | 2015 |
Beneficial effects of antidepressant mirtazapine in functional dyspepsia patients with weight loss.
Topics: Adiposity; Adult; Affect; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Checklist; China; Depression; Dyspepsia; Female; Hormones; Humans; Intra-Abdominal Fat; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Prospective Studies; Psychiatric Status Rating Scales; Time Factors; Treatment Outcome; Weight Loss | 2016 |
Effectiveness of mirtazapine as add-on to paroxetine
Topics: Adolescent; Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; China; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Mirtazapine; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome; Young Adult | 2021 |
39 other study(ies) available for paroxetine and mirtazapine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Syntheses and binding studies of new [(aryl)(aryloxy)methyl]piperidine derivatives and related compounds as potential antidepressant drugs with high affinity for serotonin (5-HT) and norepinephrine (NE) transporters.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Brain; Carrier Proteins; Fluoxetine; In Vitro Techniques; Male; Membrane Glycoproteins; Membrane Transport Proteins; Morpholines; Nerve Tissue Proteins; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Piperidines; Radioligand Assay; Rats; Rats, Wistar; Reboxetine; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Stereoisomerism; Structure-Activity Relationship; Symporters | 2003 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
An antidepressant that extends lifespan in adult Caenorhabditis elegans.
Topics: Aging; Animals; Antidepressive Agents; Caenorhabditis elegans; Caloric Restriction; Humans; Longevity; Methiothepin; Mianserin; Octopamine; Receptors, Biogenic Amine; Receptors, Serotonin, 5-HT4; Serotonin; Serotonin 5-HT4 Receptor Antagonists; Serotonin Antagonists; Signal Transduction; Starvation | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physical binding pocket induction for affinity prediction.
Topics: Binding Sites; Ligands; Models, Molecular; Neural Networks, Computer; Peptide Fragments; Protein Binding; Receptor, Serotonin, 5-HT1A | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
Topics: Animals; Blood Proteins; Buffers; Carbon Dioxide; Chemical Phenomena; Dialysis; Dogs; Drug Evaluation, Preclinical; Humans; Hydrogen-Ion Concentration; Macaca fascicularis; Mice; Osmolar Concentration; Pharmaceutical Preparations; Protein Binding; Rats; Reproducibility of Results | 2011 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
The stereoselectivity of serotonin uptake in brain tissue and blood platelets: the topography of the serotonin uptake area.
Topics: Alanine; Amphetamine; Aniline Compounds; Animals; Antidepressive Agents; Blood Platelets; Brain; Fluoxetine; Humans; Male; Methadone; Mianserin; Mirtazapine; Morpholines; Naphthalenes; Nefopam; Nomifensine; Paroxetine; Piperidines; Rabbits; Serotonin; Stereoisomerism; Tranylcypromine; Viloxazine; Zimeldine | 1986 |
Effects of the co-administration of mirtazapine and paroxetine on serotonergic neurotransmission in the rat brain.
Topics: Adrenergic alpha-Antagonists; Animals; Drug Therapy, Combination; Male; Mianserin; Mirtazapine; Paroxetine; Piperazines; Pyramidal Cells; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists | 2000 |
Does mirtazapine have a more rapid onset than SSRIs?
Topics: Antidepressive Agents, Tricyclic; Citalopram; Cross-Sectional Studies; Data Interpretation, Statistical; Depressive Disorder; Double-Blind Method; Fluoxetine; Humans; Mianserin; Mirtazapine; Paroxetine; Patient Dropouts; Placebo Effect; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Research Design; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2001 |
Serotonin transporter modulation in blood lymphocytes from patients with major depression.
Topics: Adrenergic alpha-Antagonists; Adult; Antidepressive Agents, Second-Generation; Brain; Carrier Proteins; Depressive Disorder, Major; Down-Regulation; Female; Fluoxetine; Humans; Lymphocytes; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mianserin; Mirtazapine; Nerve Tissue Proteins; Neuroimmunomodulation; Paroxetine; Radioligand Assay; Serotonin; Serotonin Plasma Membrane Transport Proteins; Treatment Outcome; Up-Regulation | 2002 |
Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption.
Topics: Animals; Antidepressive Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Brain; Chromatography, High Pressure Liquid; Cyclohexanols; Doxepin; Drug Resistance, Multiple; Gene Expression; Injections, Subcutaneous; Kidney; Liver; Male; Mianserin; Mice; Mice, Knockout; Mirtazapine; Paroxetine; Point Mutation; Spleen; Venlafaxine Hydrochloride | 2003 |
Are selective serotonin re-uptake inhibitors associated with an increased risk of self-harm by antidepressant overdose?
Topics: Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Citalopram; Cyclohexanols; Doxepin; Drug Overdose; Drug Prescriptions; Emergency Service, Hospital; Female; Fluoxetine; Humans; Imipramine; Information Services; Male; Mianserin; Mirtazapine; Paroxetine; Patient Admission; Patient Readmission; Poison Control Centers; Retrospective Studies; Risk Assessment; Scotland; Selective Serotonin Reuptake Inhibitors; Self-Injurious Behavior; Sertraline; Trazodone; Venlafaxine Hydrochloride | 2004 |
[Gynecomastia-galactorrhea during treatment with mirtazapine].
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Depressive Disorder; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Galactorrhea; Gynecomastia; Humans; Hyperprolactinemia; Male; Mianserin; Mirtazapine; Paroxetine; Risk Factors | 2004 |
Genetics in pharmacokinetics?
Topics: Antidepressive Agents, Tricyclic; Cytochrome P-450 CYP2D6; Depressive Disorder; Dose-Response Relationship, Drug; Genotype; Humans; Mianserin; Mirtazapine; Paroxetine; Pharmacogenetics; Polymorphism, Single Nucleotide; Receptor, Serotonin, 5-HT2A; Selective Serotonin Reuptake Inhibitors | 2004 |
The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression.
Topics: Adult; Catechol O-Methyltransferase; Depressive Disorder, Major; Female; Humans; Male; Methionine; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Polymorphism, Genetic; Time Factors; Valine | 2005 |
Effect of mirtazapine treatment on serotonin transporter in blood peripheral lymphocytes of major depression patients.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cell Membrane; Depressive Disorder, Major; Female; Humans; Hydroxyindoleacetic Acid; Kinetics; Lymphocytes; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mianserin; Middle Aged; Mirtazapine; Nerve Tissue Proteins; Norepinephrine; Paroxetine; Psychiatric Status Rating Scales; Serotonin; Serotonin Plasma Membrane Transport Proteins | 2005 |
An abbreviated version of the Connor-Davidson Resilience Scale (CD-RISC), the CD-RISC2: psychometric properties and applications in psychopharmacological trials.
Topics: Antidepressive Agents; Anxiety Disorders; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder, Major; Fluoxetine; Humans; Kava; Mianserin; Mirtazapine; Paroxetine; Psychometrics; Sertraline; Stress Disorders, Post-Traumatic; Surveys and Questionnaires; Venlafaxine Hydrochloride | 2007 |
Nature against nurture: calcification in the right thalamus in a young man with anorexia nervosa and obsessive-compulsive personality disorder.
Topics: Adult; Anorexia Nervosa; Benzodiazepines; Calcinosis; Combined Modality Therapy; Dominance, Cerebral; Humans; Life Change Events; Male; Mediodorsal Thalamic Nucleus; Mianserin; Mirtazapine; Obsessive-Compulsive Disorder; Olanzapine; Paroxetine; Psychotherapy; Thalamic Diseases; Tomography, X-Ray Computed | 2008 |
A case study of delayed serotonin syndrome: lessons learned.
Topics: Adrenergic alpha-Antagonists; Aged; Assisted Living Facilities; Drug Interactions; Female; Humans; Mianserin; Mirtazapine; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome; Time Factors | 2009 |
A rapid, Web-based method for obtaining patient views on effects and side-effects of antidepressants.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Data Collection; Desvenlafaxine Succinate; Duloxetine Hydrochloride; Fatigue; Fluvoxamine; Humans; Internet; Lethargy; Mianserin; Mirtazapine; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Sleep Stages; Thiophenes; Venlafaxine Hydrochloride | 2011 |
Treatment of depression as part of end-of-life care.
Topics: Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Carcinoma, Squamous Cell; Depression; Drug Therapy, Combination; Esophageal Neoplasms; Fatal Outcome; Female; Humans; Mianserin; Mirtazapine; Paroxetine; Terminal Care | 2008 |
Time to discontinuation among the three second-generation antidepressants in a naturalistic outpatient setting of depression.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder; Female; Humans; Korea; Male; Medication Adherence; Mianserin; Middle Aged; Mirtazapine; Outpatients; Paroxetine; Retrospective Studies; Venlafaxine Hydrochloride | 2011 |
Influence of body mass index on the choice of therapy for depression and follow-up care.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Body Mass Index; Choice Behavior; Cohort Studies; Depression; Female; Fluoxetine; Follow-Up Studies; Humans; Logistic Models; Male; Mianserin; Middle Aged; Mirtazapine; Obesity; Paroxetine; Psychotherapy; Young Adult | 2013 |
New onset alcohol dependence linked to treatment with selective serotonin reuptake inhibitors.
Topics: Alcoholism; Antidepressive Agents, Tricyclic; Depressive Disorder; Drug Substitution; Female; Humans; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2013 |
Decreased sensitivity to paroxetine-induced inhibition of peripheral blood mononuclear cell growth in depressed and antidepressant treatment-resistant patients.
Topics: Adult; Biomarkers; Cell Proliferation; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Humans; Integrin beta3; Male; Mianserin; Middle Aged; Mirtazapine; Monocytes; Paroxetine; Peptide Fragments; Serotonin Plasma Membrane Transport Proteins | 2016 |
Effect of antidepressants on spatial memory deficit induced by dizocilpine.
Topics: Animals; Antidepressive Agents; Cell Count; Citalopram; Cognition; Cognitive Dysfunction; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Fluvoxamine; Hippocampus; Interneurons; Male; Maze Learning; Memory Disorders; Mianserin; Mirtazapine; Paroxetine; Rats; Rats, Sprague-Dawley; Schizophrenia; Schizophrenic Psychology; Sertraline; Spatial Memory; Venlafaxine Hydrochloride | 2016 |
Discontinuation and dose adjustment of metoprolol after metoprolol-paroxetine/fluoxetine co-prescription in Dutch elderly.
Topics: Aged; Aged, 80 and over; Citalopram; Cohort Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Drug Prescriptions; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Metoprolol; Middle Aged; Mirtazapine; Netherlands; Paroxetine | 2018 |
Association of Antidepressant Use With Drug-Related Extrapyramidal Symptoms: A Pharmacoepidemiological Study.
Topics: Antidepressive Agents; Basal Ganglia Diseases; Bupropion; Case-Control Studies; Citalopram; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Pharmacoepidemiology; Sertraline; United States; Venlafaxine Hydrochloride | 2018 |
Short-Term Safety of Paroxetine Plus Low-Dose Mirtazapine During Lactation.
Topics: Adult; Breast Feeding; Depression, Postpartum; Female; Humans; Infant; Infant, Newborn; Milk, Human; Mirtazapine; Paroxetine; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Young Adult | 2019 |
Combination of mirtazapine and paroxetine: possible clinically demonstrated interaction?
Topics: Antidepressive Agents; Cytochrome P-450 Enzyme System; Depression; Drug Interactions; Humans; Mirtazapine; Paroxetine | 2019 |
A case of mood disorder with severe side effects of antidepressants in association with resistance to thyroid hormone beta with a THRB mutation.
Topics: Aged; Antidepressive Agents; Female; Humans; Mirtazapine; Mood Disorders; Mutation; Paroxetine; Quetiapine Fumarate; Thyroid Hormone Receptors beta; Thyroid Hormone Resistance Syndrome; Thyroid Hormones; Venlafaxine Hydrochloride | 2022 |